Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Phase II Umbrella Study of Novel Anti-cancer Agents in Patients With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy. (HUDSON)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03334617
Recruitment Status : Recruiting
First Posted : November 7, 2017
Last Update Posted : September 25, 2019
Sponsor:
Information provided by (Responsible Party):
AstraZeneca

Tracking Information
First Submitted Date  ICMJE September 22, 2017
First Posted Date  ICMJE November 7, 2017
Last Update Posted Date September 25, 2019
Actual Study Start Date  ICMJE December 18, 2017
Estimated Primary Completion Date July 30, 2021   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: March 26, 2019)
Assessment of the efficacy of each treatment by evaluation of objective response rate [ Time Frame: 12 weeks ]
Endpoint based on Response Evaluation Criteria in Solid Tumours (RECIST 1.1) Objective response rate (ORR)
Original Primary Outcome Measures  ICMJE
 (submitted: November 3, 2017)
Assessment of the efficacy of each treatment by evaluation of objective response rate [ Time Frame: 12 weeks ]
Endpoint based on modified Response Evaluation Criteria in Solid Tumours (RECIST 1.1) Objective response rate (ORR)
Change History Complete list of historical versions of study NCT03334617 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures  ICMJE
 (submitted: March 26, 2019)
  • Disease control rate (DCR) using RECIST 1.1 assessment for the anti-tumour activity of each therapy. [ Time Frame: Through to study completion, up to 3.5 years. ]
    Assessment of the anti-tumour activity of each therapy.
  • Best percentage change in tumour size using RECIST 1.1 assessment for the anti-tumour activity of each therapy [ Time Frame: Through to study completion, up to 3.5 years. ]
    Assessment of the anti-tumour activity of each therapy.
  • Duration of response (DoR) using RECIST 1.1 assessment for the anti-tumour activity of each therapy. [ Time Frame: Through to study completion, up to 3.5 years ]
    Assessment of the anti-tumour activity of each therapy.
  • Progression free survival (PFS) using RECIST 1.1 assessment for the anti-tumour activity of each therapy. [ Time Frame: Through to study completion, up to 3.5 years. ]
    Assessment of the anti-tumour activity of each therapy.
  • Overall surival (OS) [ Time Frame: Through to study completion, up to 4.5 years. ]
    Assessment of the anti-tumour activity of each therapy.
Original Secondary Outcome Measures  ICMJE
 (submitted: November 3, 2017)
  • Disease control rate (DCR) using modified RECIST 1.1 assessment for the anti-tumour activity of each therapy. [ Time Frame: Through to study completion, up to 3.5 years. ]
    Assessment of the anti-tumour activity of each therapy.
  • Best percentage change in tumour size using modified RECIST 1.1 assessment for the anti-tumour activity of each therapy [ Time Frame: Through to study completion, up to 3.5 years. ]
    Assessment of the anti-tumour activity of each therapy.
  • Duration of response (DoR) using modified RECIST 1.1 assessment for the anti-tumour activity of each therapy. [ Time Frame: Through to study completion, up to 3.5 years ]
    Assessment of the anti-tumour activity of each therapy.
  • Progression free survival (PFS) using modified RECIST 1.1 assessment for the anti-tumour activity of each therapy. [ Time Frame: Through to study completion, up to 3.5 years. ]
    Assessment of the anti-tumour activity of each therapy.
  • Overall surival (OS) [ Time Frame: Through to study completion, up to 4.5 years. ]
    Assessment of the anti-tumour activity of each therapy.
Current Other Pre-specified Outcome Measures
 (submitted: November 3, 2017)
Incidence of adverse events/serious adverse events to assess the safety and tolerability of each treatment [ Time Frame: Through to study completion, up to 3.5 years. ]
Physical examinations, laboratory findings, and vital signs AEs/SAEs collected throughout the study, from informed consent until the safety follow-up visit
Original Other Pre-specified Outcome Measures Same as current
 
Descriptive Information
Brief Title  ICMJE Phase II Umbrella Study of Novel Anti-cancer Agents in Patients With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy.
Official Title  ICMJE An Open-Label, Multi-Drug, Biomarker-Directed, Multi-Centre Phase II Umbrella Study in Patients With Non-Small Cell Lung Cancer, Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy (HUDSON).
Brief Summary This is an open-label, multi-centre, umbrella Phase II study in patients with metastatic NSCLC who have progressed on an anti-PD-1/PD-L1 containing therapy. This study is modular in design, allowing initial assessment of the efficacy, safety, and tolerability of multiple treatment arms.
Detailed Description

This is an open-label, multi-centre, umbrella Phase II study in patients with metastatic non-small cell lung cancer (NSCLC) who have progressed on an anti-programmed cell death-1/anti-programmed cell death ligand 1 (anti-PD-1/PD-L1) containing therapy. This study is modular in design, consisting of a number of treatment cohorts, allowing evaluation of the efficacy, safety, and tolerability of multiple treatment arms. There is currently no established therapy for patients who have received immune checkpoint inhibitors and platinum-doublet therapies, and novel treatments are urgently needed.

This protocol has a modular design, with the potential for future treatment arms to be added via protocol amendment.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Intervention Model Description:

This is an open-label, multi-centre, umbrella Phase II study in patients with metastatic NSCLC who have progressed on an anti-PD-1/PD-L1 containing therapy. This study is modular in design, allowing initial assessment of the efficacy, safety, and tolerability of multiple treatment arms.

Within each module, there will be treatment cohorts.

Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Non-Small Cell Lung Cancer
Intervention  ICMJE
  • Drug: Durvalumab
    Durvalumab given IV at 1500 mg Q4W ±2 days
  • Drug: AZD9150
    AZD9150 given IV at 200mg every other day of a 1-week lead-in period followed by QW
  • Drug: AZD6738
    AZD6738 given orally at 240mg twice daily in Cycle 0 Days 1-7, followed by 7 days on treatment in each cycle between Days 22-28
  • Drug: Vistusertib
    Vistusertib (AZD2014) given orally at a dose of 125 mg BD on an intermittent dosing schedule of 2 days on, 5 days off
  • Drug: Olaparib
    Olaparib (AZD2281) given orally at 300 mg BD
  • Drug: Oleclumab
    Oleclumab given at dose level 1 for 2 cycles and then dose level 2 thereafter
Study Arms  ICMJE
  • Experimental: Durvalumab + olaparib
    Durvalumab given in combination with olaparib .
    Interventions:
    • Drug: Durvalumab
    • Drug: Olaparib
  • Experimental: Durvalumab + AZD9150
    Durvalumab given in combination with AZD9150.
    Interventions:
    • Drug: Durvalumab
    • Drug: AZD9150
  • Experimental: Durvalumab + AZD6738
    Durvalumab given in combination with AZD6738.
    Interventions:
    • Drug: Durvalumab
    • Drug: AZD6738
  • Experimental: Durvalumab + vistusertib
    Durvalumab given in combination with Vistusertib (AZD2014).
    Interventions:
    • Drug: Durvalumab
    • Drug: Vistusertib
  • Experimental: Durvalumab + Oleclumab
    Durvalumab given in combination with Oleclumab
    Interventions:
    • Drug: Durvalumab
    • Drug: Oleclumab
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: October 19, 2018)
260
Original Estimated Enrollment  ICMJE
 (submitted: November 3, 2017)
200
Estimated Study Completion Date  ICMJE July 30, 2021
Estimated Primary Completion Date July 30, 2021   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion criteria:

  • At least 18 years of age at the time of signing the informed consent form.
  • Patient must have histologically or cytologically confirmed metastatic or locally advanced and recurrent NSCLC which is progressing.
  • Patients eligible for second- or later-line therapy, who must have received an antiPD1/PD-L1 containing therapy and a platinum-doublet regimen for locally advanced or metastatic NSCLC either separately or in combination. Prior durvalumab is acceptable. The patient must have had disease progression on a prior line of antiPD1/PD-L1 therapy.
  • ECOG/WHO performance status of 0 to 1, and a minimum life expectancy of 12 weeks.
  • Patient must have at least 1 lesion that can be accurately measured. A previously irradiated lesion can be considered a target lesion if the lesion has clearly progressed.
  • Evidence of post-menopausal status or negative urinary or serum pregnancy test for female pre-menopausal patients.

Exclusion Criteria:

  • Patients whose tumour samples have targetable alterations in EGFR and/or ALK are excluded. In addition, patients whose tumour samples are known to have targetable alterations in ROS1, BRAF, MET or RET, are to be excluded.
  • Active or prior documented autoimmune or inflammatory disorders.
  • Active infection including hepatitis B (known positive HBV surface antigen [HBsAg] result), hepatitis C, or human immunodeficiency virus (positive HIV 1/2 antibodies).
  • Female patients who are pregnant or breastfeeding, or male or female patients of reproductive potential who are not willing to employ effective birth control.
  • Known allergy or hypersensitivity to any of the study drugs or any of the study drug excipients.
  • Patient has spinal cord compression or symptomatic brain metastases.
  • Any concurrent chemotherapy, immunotherapy, biologic or hormonal therapy for cancer treatment. Patients may receive treatment with bisphosphonates or receptor activator of nuclear factor kappa-Β ligand (RANKL) inhibitors for the treatment of bone metastases.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years to 99 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: AstraZeneca Clinical Study Information Center 1-877-240-9479 information.center@astrazeneca.com
Contact: Cancer Study Locator 1-877-400-4656 AstraZeneca@emergingmed.com
Listed Location Countries  ICMJE Austria,   Canada,   France,   Germany,   Israel,   Korea, Republic of,   United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03334617
Other Study ID Numbers  ICMJE D6185C00001
2017-002208-28 ( EudraCT Number )
138050 ( Registry Identifier: IND )
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
IPD Sharing Statement  ICMJE Not Provided
Responsible Party AstraZeneca
Study Sponsor  ICMJE AstraZeneca
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Principal Investigator: John Heymach, M.D, Ph.D The University of Texas MD Anderson Cancer Center
PRS Account AstraZeneca
Verification Date September 2019

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP